Dasabuvir
drugOn this page
Also known as ABT-333
Summary
Dasabuvir (CHEMBL3137312) is an approved small-molecule antiviral drug (ATC J05AP09); indicated across 4 conditions including viral infectious disease and chronic hepatitis c virus infection.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: J05AP09
- Indications: 4 conditions
- Clinical trials: 39
- Chemistry: 493.6 Da · C26H27N3O5S
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3137312 |
| Name | Dasabuvir |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 56640146 |
| ChEBI | CHEBI:85182 |
| ATC | J05AP09 |
| Molecular formula | C26H27N3O5S |
| Molecular weight | 493.6 |
| InChIKey | NBRBXGKOEOGLOI-UHFFFAOYSA-N |
SMILES: CC(C)(C)C1=CC(=CC(=C1OC)C2=CC3=C(C=C2)C=C(C=C3)NS(=O)(=O)C)N4C=CC(=O)NC4=O
IUPAC name: N-[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamide
ChEBI definition: A member of the class of pyrimidone, which is (as the monohydrate of its sodium salt) in combination with ombitasvir, paritaprevir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.
Pharmacological roles (ChEBI): antiviral drug, nonnucleoside hepatitis C virus polymerase inhibitor.
Also known as: ABT-333, Dasabuvir, DASABUVIR, dasabuvir
Parent form; salt/anhydrous children: CHEMBL3544985, CHEMBL5572094
Patent coverage: 429 distinct patent families (1,088 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 921 (85%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Protein cereblon.
Bioactivity
ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| CRBN | 5.33 | Ki | 4710 | nM | CHEMBL_ACT_22446501 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
4 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| viral infectious disease | 4 | MONDO:0005108 | EFO:0000763 |
| chronic hepatitis C virus infection | 3 | MONDO:0005354 | EFO:0004220 |
| hepatitis C virus infection | 3 | MONDO:0005231 | EFO:0003047 |
| hepatitis B virus infection | 2 | MONDO:0005344 | EFO:0004197 |
Clinical trials
Total trials: 39.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 11 |
| PHASE2 | 9 |
| PHASE1 | 7 |
| Not specified | 7 |
| PHASE2/PHASE3 | 3 |
| PHASE4 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02460133 | PHASE4 | ACTIVE_NOT_RECRUITING | Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment |
| NCT02950870 | PHASE4 | UNKNOWN | Efficacy Study to Evaluate the Effect of New Antiviral Drugs on HCV Infection. |
| NCT01773070 | PHASE3 | COMPLETED | A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study |
| NCT01939197 | PHASE2/PHASE3 | COMPLETED | A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection |
| NCT02167945 | PHASE3 | COMPLETED | A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection |
| NCT02207088 | PHASE3 | COMPLETED | Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease |
| NCT02216422 | PHASE3 | COMPLETED | A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection |
| NCT02219477 | PHASE3 | COMPLETED | A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis |
| NCT02219490 | PHASE3 | COMPLETED | A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection |
| NCT02219503 | PHASE3 | COMPLETED | A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis |
| NCT02476617 | PHASE3 | COMPLETED | Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults |
| NCT02486406 | PHASE2/PHASE3 | COMPLETED | A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects |
| NCT02517528 | PHASE3 | COMPLETED | ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis |
| NCT02555943 | PHASE2/PHASE3 | COMPLETED | DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO) |
| NCT02582632 | PHASE3 | COMPLETED | A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults |
| NCT02634008 | PHASE3 | COMPLETED | Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P |
| NCT00726882 | PHASE2 | COMPLETED | A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies |
| NCT00851890 | PHASE2 | COMPLETED | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection |
| NCT01074008 | PHASE2 | COMPLETED | A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 |
| NCT01306617 | PHASE2 | COMPLETED | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection |
| NCT01464827 | PHASE2 | COMPLETED | ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients |
| NCT01563536 | PHASE2 | COMPLETED | Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects |
| NCT01911845 | PHASE2 | COMPLETED | An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine |
| NCT02194998 | PHASE2 | TERMINATED | Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy |
| NCT02493855 | PHASE2 | COMPLETED | Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults |
| NCT00696904 | PHASE1 | COMPLETED | Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects |
| NCT00768690 | PHASE1 | COMPLETED | A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333 |
| NCT00895102 | PHASE1 | COMPLETED | Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers |
| NCT00909636 | PHASE1 | COMPLETED | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet |
| NCT00919490 | PHASE1 | COMPLETED | A Study of Single Dose of ABT-333 in Healthy Male Adults |
| NCT02052349 | PHASE1 | COMPLETED | Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects |
| NCT02534870 | PHASE1 | COMPLETED | Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects |
| NCT02333292 | Not specified | COMPLETED | Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions |
| NCT02581163 | Not specified | COMPLETED | Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium |
| NCT02581189 | Not specified | COMPLETED | Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada |
| NCT02582671 | Not specified | COMPLETED | The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland |
| NCT02725866 | Not specified | COMPLETED | Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C |
| NCT02803138 | Not specified | COMPLETED | Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C |
| NCT03122132 | Not specified | COMPLETED | Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).